209 related articles for article (PubMed ID: 16948449)
1. Relationship between preheparin lipoprotein lipase mass concentration in serum and bare metal stent restenosis.
Hitsumoto T; Takahashi M; Iizuka T; Shirai K
J Cardiol; 2006 Aug; 48(2):65-73. PubMed ID: 16948449
[TBL] [Abstract][Full Text] [Related]
2. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of preheparin serum lipoprotein lipase mass in normocholesterolemic patients with coronary artery disease].
Hitsumoto T; Yoshinaga K; Sakurai T; Aoyagi K; Matsumoto J; Iizuka T; Kaku M; Sugiyama Y; Kanai M; Uchi T; Noike H; Ohsawa H; Watanabe H; Shirai K
J Cardiol; 2002 Jul; 40(1):1-9. PubMed ID: 12166243
[TBL] [Abstract][Full Text] [Related]
4. Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries.
Bonello L; De Labriolle A; Lemesle G; Roy P; Steinberg DH; Slottow TL; Xue Z; Torguson R; Kaneshige K; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
Am J Cardiol; 2009 Feb; 103(4):496-500. PubMed ID: 19195509
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.
Halkin A; Selzer F; Marroquin O; Laskey W; Detre K; Cohen H
J Invasive Cardiol; 2006 Dec; 18(12):577-83. PubMed ID: 17197706
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of preintervention C-reactive protein on clinical outcome after directional coronary atherectomy followed by stent implantation.
Niccoli G; Ferrante G; Mongiardo R; Perfetti M; Belloni F; Burzotta F; Porto I; Leone AM; Rebuzzi AG; Crea F
Cardiovasc Revasc Med; 2007; 8(3):156-60. PubMed ID: 17765643
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
Qasim A; Cosgrave J; Latib A; Colombo A
Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
[TBL] [Abstract][Full Text] [Related]
9. Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation.
Canibus P; Faloia E; Piva T; Muçai A; Serenelli M; Perna GP; Boscaro M; Piva R
Metabolism; 2008 May; 57(5):593-7. PubMed ID: 18442619
[TBL] [Abstract][Full Text] [Related]
10. Use and long-term outcome of bare metal stent implantation in the drug-eluting stent era.
Fujimoto H; Dohi T; Masuda J; Mitani H; Fujimoto Y; Maehara A; Nishiyama S; Nakanishi S; Yamaguchi T; Ishiwata S; Ohno M
J Cardiol; 2007 Jun; 49(6):305-12. PubMed ID: 17633567
[TBL] [Abstract][Full Text] [Related]
11. Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry.
Yan BP; Ajani AE; New G; Duffy SJ; Farouque O; Shaw J; Sebastian M; Lew R; Brennan A; Andrianopoulos N; Reid C; Clark DJ;
Int J Cardiol; 2008 Nov; 130(3):374-9. PubMed ID: 18706719
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
13. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
[TBL] [Abstract][Full Text] [Related]
14. Serum concentration of insulin-like growth factor-I, but not tumor necrosis factor-alpha, measured twelve months after stenting of the infarct-related artery, is associated with in-stent restenosis.
Szkodzinski J; Hudzik B; Romanowski W; Wilczek K; Danikiewicz A; Gasior M; Polonski L; Zubelewicz-Szkodzinska B
J Biol Regul Homeost Agents; 2010; 24(2):149-56. PubMed ID: 20487628
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB;
Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions.
Li JJ; Qin XW; Yang XC; Li ZC; Zeng HS; Xu B; Gao Z; Wu YJ; Zhang X; Zhang CY
Clin Chim Acta; 2008 Oct; 396(1-2):38-42. PubMed ID: 18634770
[TBL] [Abstract][Full Text] [Related]
17. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.
Delhaye C; Sudre A; Lemesle G; Maréchaux S; Broucqsault D; Hennache B; Bauters C; Lablanche JM
Cardiovasc Revasc Med; 2009; 10(3):144-50. PubMed ID: 19595394
[TBL] [Abstract][Full Text] [Related]
18. Remnant-like lipoprotein particle level and insulin resistance are associated with in-stent restenosis in patients with stable angina.
Kato T; Inoue T; Inagaki H; Hashimoto S; Hikichi Y; Tanaka A; Isobe M; Node K
Coron Artery Dis; 2007 Jun; 18(4):319-22. PubMed ID: 17496497
[TBL] [Abstract][Full Text] [Related]
19. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation.
Zellweger MJ; Kaiser C; Brunner-La Rocca HP; Buser PT; Osswald S; Weiss P; Mueller-Brand J; Pfisterer ME;
J Nucl Med; 2008 Apr; 49(4):550-6. PubMed ID: 18344439
[TBL] [Abstract][Full Text] [Related]
20. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
